DE602005021766D1 - Verfahren zur behandlung von atherosklerose - Google Patents

Verfahren zur behandlung von atherosklerose

Info

Publication number
DE602005021766D1
DE602005021766D1 DE602005021766T DE602005021766T DE602005021766D1 DE 602005021766 D1 DE602005021766 D1 DE 602005021766D1 DE 602005021766 T DE602005021766 T DE 602005021766T DE 602005021766 T DE602005021766 T DE 602005021766T DE 602005021766 D1 DE602005021766 D1 DE 602005021766D1
Authority
DE
Germany
Prior art keywords
treatment
atherosclerosis
autoimmune diseases
inflammatory disorders
provides method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005021766T
Other languages
English (en)
Inventor
Bernard Mach
Yann Dean
Marie Kosco-Vilbois
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novimmune SA
Original Assignee
Novimmune SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novimmune SA filed Critical Novimmune SA
Publication of DE602005021766D1 publication Critical patent/DE602005021766D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE602005021766T 2004-04-06 2005-04-06 Verfahren zur behandlung von atherosklerose Active DE602005021766D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55994404P 2004-04-06 2004-04-06
PCT/US2005/011767 WO2005099755A2 (en) 2004-04-06 2005-04-06 Methods of treating autoimmune and inflammatory diseases

Publications (1)

Publication Number Publication Date
DE602005021766D1 true DE602005021766D1 (de) 2010-07-22

Family

ID=35150504

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005021766T Active DE602005021766D1 (de) 2004-04-06 2005-04-06 Verfahren zur behandlung von atherosklerose

Country Status (20)

Country Link
US (1) US20050265993A1 (de)
EP (1) EP1737490B1 (de)
JP (1) JP4812748B2 (de)
KR (1) KR20070036035A (de)
CN (2) CN102847149B (de)
AT (1) ATE470453T1 (de)
AU (1) AU2005232653B2 (de)
CA (1) CA2563260C (de)
DE (1) DE602005021766D1 (de)
DK (1) DK1737490T3 (de)
EA (1) EA012725B1 (de)
ES (1) ES2348984T3 (de)
HK (1) HK1099525A1 (de)
IL (2) IL178478A (de)
MX (1) MXPA06011526A (de)
NO (2) NO340627B1 (de)
PT (1) PT1737490E (de)
UA (2) UA103594C2 (de)
WO (1) WO2005099755A2 (de)
ZA (1) ZA200608884B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4939899B2 (ja) * 2006-10-30 2012-05-30 オムロンオートモーティブエレクトロニクス株式会社 導電端子の溶接方法、および導電端子構造
JP2010524851A (ja) † 2007-04-03 2010-07-22 マイクロメット アーゲー 種間特異的結合ドメイン
BR112012029739A2 (pt) * 2010-05-24 2016-08-09 Indena Spa polissacarídeo da semente de tamarindo para uso no tratamento de infecções microbianas
EP2640750A1 (de) * 2010-11-16 2013-09-25 Boehringer Ingelheim International GmbH Mittel und verfahren zur behandlung von mit bcma-expression korrelierenden erkrankungen
JP2015091761A (ja) * 2012-02-23 2015-05-14 国立大学法人大阪大学 中枢神経の損傷を治療するための組成物およびその利用
US9664690B1 (en) * 2013-08-28 2017-05-30 The National Institute For Biotechnology I Molecular diagnostic kits for evaluating stress
CN113507935A (zh) * 2018-10-16 2021-10-15 得克萨斯州大学系统董事会 用于诊断和治疗癌症及其他疾病的对致病性胞外基质的鉴定和靶向
JP2022512709A (ja) * 2018-10-31 2022-02-07 ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー 炎症性疾患及び自己免疫疾患を処置する組成物及び方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025477A (en) * 1986-03-31 2000-02-15 Calenoff; Emanuel Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
JPH08510451A (ja) * 1993-05-13 1996-11-05 ネオルックス コーポレイション 異常増殖性平滑筋細胞に関連した病因の予防及び治療
US7041289B1 (en) * 1997-12-05 2006-05-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for treating established spontaneous auto-immune diseases in mammals
GB2380127A (en) * 2001-09-26 2003-04-02 Isis Innovation Treatment of chronic joint inflammation
US20030216551A1 (en) * 2002-03-08 2003-11-20 Diabetogen Biosciences Inc. Fully human anti-CD3 monoclonal antibodies
AU2005206746B2 (en) * 2004-01-08 2008-08-28 Regents Of The University Of California Regulatory t cells suppress autoimmunity

Also Published As

Publication number Publication date
NO20170737A1 (no) 2006-11-06
DK1737490T3 (da) 2010-10-04
NO20064896L (no) 2006-11-06
EA200601871A1 (ru) 2007-04-27
WO2005099755A3 (en) 2006-04-27
CN102847149A (zh) 2013-01-02
CN1972714A (zh) 2007-05-30
IL209338A0 (en) 2011-01-31
MXPA06011526A (es) 2007-03-21
EP1737490A2 (de) 2007-01-03
PT1737490E (pt) 2010-08-31
ES2348984T3 (es) 2010-12-21
UA89780C2 (ru) 2010-03-10
EA012725B1 (ru) 2009-12-30
CA2563260A1 (en) 2005-10-27
JP2007532565A (ja) 2007-11-15
CN102847149B (zh) 2016-01-20
WO2005099755A2 (en) 2005-10-27
CA2563260C (en) 2013-05-28
CN1972714B (zh) 2012-10-03
NO340627B1 (no) 2017-05-15
US20050265993A1 (en) 2005-12-01
HK1099525A1 (en) 2007-08-17
JP4812748B2 (ja) 2011-11-09
KR20070036035A (ko) 2007-04-02
ATE470453T1 (de) 2010-06-15
UA103594C2 (ru) 2013-11-11
IL178478A0 (en) 2007-02-11
AU2005232653A1 (en) 2005-10-27
AU2005232653B2 (en) 2010-12-16
IL178478A (en) 2010-12-30
ZA200608884B (en) 2008-06-25
EP1737490B1 (de) 2010-06-09

Similar Documents

Publication Publication Date Title
DE602005021766D1 (de) Verfahren zur behandlung von atherosklerose
ATE544748T1 (de) Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
ATE540949T1 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
DE602006018583D1 (de) Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
ATE501721T1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
DE602006019753D1 (de) Verfahren und gerät zur behandlung von aneurysmen der a. thoracica
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
DE602005006938D1 (de) Gebrauchslimitierendes elektronisches Schlüsselsystem für Plasmagerät zur Behandlung von Gewebeoberflächen
DE602004023829D1 (de) Verfahren zur behandlung von sinuskopfschmerzen
DE602004021790D1 (de) Verfahren zur behandlung von parkinson-krankheit
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
DE502006004066D1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
DE502005010499D1 (de) Implantat zur Behandlung von Fettsucht
DE60330161D1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE60223688D1 (de) Verfahren zur behandlung von multiplem myelom
DE602005015160D1 (de) Stent-Graft zur Behandlung von Aneurysmen
DE602005013650D1 (de) Proteinhydrolysat zur behandlung von müdigkeit
ATE410235T1 (de) Behandlung von ballastwasser
IL177825A0 (en) Natural igm antibodies and inhibitors thereof
ATE446757T1 (de) 1-ä2h-1-benzopyran-2-one-8-ylü- piperazinderivative zur behandlung von bewegungsstörungen
DE602004011275D1 (de) Zusammensetzungen und Verfahren zur Behandlung von Fettleibigkeit
ATE427754T1 (de) Verwendung von il-17f zur behandlung und/oder pravention von neurologischen erkrankungen
DE602005026848D1 (de) Verfahren zur reifung und/oder maturierung, konserm durchführen des verfahrens